Related Experiment Video
Updated: Jul 20, 2026
06:35
A Mouse Model to Investigate the Role of Cancer-Associated Fibroblasts in Tumor Growth
Published on: December 22, 2020
Stroma-derived factor (SDF-1/CXCL12) and human tumor pathogenesis.
Ilona Kryczek1, Shuang Wei, Evan Keller
1Department of Surgery, University of Michigan School of Medicine, Ann Arbor, MI 48109-0669, USA.
American Journal of Physiology. Cell Physiology
|September 1, 2006
Summary
The stroma-derived factor (SDF-1/CXCL12) pathway fuels cancer growth, spread, and immune evasion. Targeting this CXCL12/CXCR4 axis offers a promising strategy for developing new anti-cancer therapies.
Area of Science:
- Oncology
- Molecular Biology
- Immunology
Background:
- The chemokine stroma-derived factor (SDF-1/CXCL12) is implicated in various aspects of tumor pathogenesis.
- CXCL12 promotes tumor growth, malignancy, angiogenesis, metastasis, and immune suppression within the tumor microenvironment.
Purpose of the Study:
- To review the pathological roles and characteristics of the CXCL12/CXCR4 pathway in the tumor microenvironment.
- To discuss therapeutic strategies targeting the CXCL12/CXCR4 axis for cancer treatment.
Main Methods:
- Literature review of studies investigating the CXCL12/CXCR4 pathway in cancer.
- Analysis of the molecular mechanisms underlying CXCL12/CXCR4 involvement in tumor progression.
- Synthesis of current and potential therapeutic approaches targeting this pathway.
Main Results:
- The CXCL12/CXCR4 pathway is a critical mediator of tumor growth, angiogenesis, metastasis, and immunosuppression.
- Evidence supports the CXCL12/CXCR4 axis as a significant target for anti-cancer drug development.
Conclusions:
- The CXCL12/CXCR4 pathway is a key player in tumor pathogenesis and represents a viable target for novel cancer therapies.
- Further research into targeting this axis could lead to more effective anti-cancer treatments.
Related Concept Videos
01:01Regulation of Hematopoietic Stem Cells
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
02:17The Tumor Microenvironment
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
01:15Differentiation of Common Myeloid Progenitor Cells
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...